Scientific deep-dive

What Is Mazdutide? The Obesity Drug Approved in China, Not the US

Mazdutide is a glucagon/GLP-1 dual agonist approved in China for weight management but unavailable in the US. What the approval authorizes, how it differs from tirzepatide and retatrutide, and why an approval abroad doesn't make a US-sold vial legitimate.

By Eli Marsden · Founding Editor
Editorially reviewed & fact-checked against primary sources · How we verify contentLast reviewed
6 min read·6 citations

Mazdutide is a once-weekly glucagon/GLP-1 dual agonist developed by Innovent Biologics under license from Eli Lilly. It is unusual among the drugs people research: it is not a pipeline compound waiting on trial results, and it is not a gray-market peptide. It is an approved medicine — approved by China's NMPA for chronic weight management, and reported in the literature as a first approval for its class [1]. It has no US approval, which is the whole reason it is confusing. The closest comparison is survodutide, which targets the identical receptor pair but is approved nowhere.

Approved, but not where you are

Mazdutide (brand name Xinermei) received Chinese regulatory approval in June 2025 for long-term weight management, alongside diet and physical activity, in adults with a BMI of at least 28 kg/m², or a BMI of at least 24 kg/m² plus at least one weight-related comorbidity (China uses lower BMI cutoffs than the US). A second approval, in September 2025, covers glycemic control in adults with type 2 diabetes [1]. That is a genuine marketing authorization from a major regulator — not an emergency pathway and not a research exemption.

An approval in one country is not an approval in yours. A Chinese NMPA authorization does not create a US prescription pathway, does not make importing it lawful for personal use by default, and does not mean a US pharmacy can compound it. If a US seller cites the Chinese approval as evidence their product is legitimate, they are citing a decision that does not apply to what they are selling.

What it does, mechanically

Mazdutide is described as a mammalian oxyntomodulin analog. Alongside the GLP-1 effects familiar from semaglutide — insulin secretion, lower blood glucose, reduced appetite — the glucagon-receptor arm may increase energy expenditure and improve hepatic fat metabolism [1]. That is the same second lever retatrutide pulls, except retatrutide adds a third receptor (GIP) and mazdutide does not.

Where mazdutide sits among multi-receptor agonists
DrugReceptorsStatus
SemaglutideGLP-1FDA approved
TirzepatideGIP + GLP-1FDA approved
MazdutideGlucagon + GLP-1Approved in China; no US approval
SurvodutideGlucagon + GLP-1Investigational
RetatrutideGIP + GLP-1 + glucagonInvestigational

The trial evidence

The pivotal work was conducted in Chinese adults. In GLORY-1, published in the New England Journal of Medicine in 2025, once-weekly mazdutide 4 mg and 6 mg produced mean weight changes of −11.0% and −14.0% at 48 weeks versus +0.3% on placebo [2]. A second phase 3 trial, GLORY-2, tested a higher 9 mg dose in adults with a BMI of at least 30 and reported −16.65% at 60 weeks versus −1.50% on placebo, with frequent gastrointestinal side effects [4]. For type 2 diabetes, a placebo-controlled trial [5] and a head-to-head trial in which mazdutide beat dulaglutide 1.5 mg on both HbA1c and weight [3] were published back to back in Nature in 2026.

One limitation is worth stating plainly rather than burying: the efficacy and safety dataset is predominantly Chinese. That is not a criticism of the trials, which were designed for the market that approved the drug. It does mean the usual caution about generalizing across populations applies more than it would for a drug with a multi-region phase 3 program. The one published efficacy trial outside China so far is Eli Lilly's US phase 2 in 179 adults, which reported −15.6% on 10 mg and −18.1% on 16 mg at 32 weeks, with 20% of the 16 mg group stopping treatment for adverse events [6] — a dose-finding study, not a registration trial.

“Mazdutide peptide” is not the approved product

A meaningful share of English-language searches for mazdutide pair it with the word “peptide” — the same pattern that surrounds every unapproved-in-the-US obesity compound. Material sold that way is not the Chinese approved product routed to you; it is unapproved material of unverified identity and purity. The approval belongs to a specific manufactured product under a specific regulator, and it does not transfer to a vial from a research-chemical vendor.

Frequently Asked Questions

No. It is approved by China's NMPA for chronic weight management (June 2025) and for glycemic control in type 2 diabetes (September 2025). It has no US approval, so there is no US prescription or pharmacy route. Eli Lilly has run US phase 1 and phase 2 trials, but no FDA filing had been announced as of October 2026.
Both hit two receptors, but different ones. Tirzepatide is GIP plus GLP-1. Mazdutide is glucagon plus GLP-1, and the glucagon arm is associated with increased energy expenditure and improved liver fat rather than added insulin secretion.
Retatrutide adds a third receptor. Mazdutide is glucagon plus GLP-1; retatrutide is glucagon plus GLP-1 plus GIP. Mazdutide is approved in China, while retatrutide remains investigational everywhere.
Not through a lawful prescription route, because it has no US approval. A Chinese approval does not create a US pathway, and it does not make a compounded or imported version of it an approved product.

References

  1. 1.Shirley M. Mazdutide: First Approval. Drugs. 2025. PMID: 41028652.
  2. 2.Ji L, Jiang H, Bi Y, Li H, Tian J, Liu D, et al. Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight. N Engl J Med. 2025. PMID: 40421736.
  3. 3.Guo L, Zhang B, Xue X, Zhang X, Cai H, Jiang H, et al.; DREAMS-2 investigators. Mazdutide versus dulaglutide in Chinese adults with type 2 diabetes. Nature. 2026. PMID: 41407860.
  4. 4.Gao L, Jiang H, Cai H, Tian J, Shi B, Qiu W, et al.; GLORY-2 Trial Investigators. Treatment With 9-mg Mazdutide for Weight Reduction in Chinese Adults With Obesity: The GLORY-2 Randomized Clinical Trial. JAMA. 2026. PMID: 42251595.
  5. 5.Zhu D, Zhao J, Cai H, Chu X, Xiu S, Song C, et al. Mazdutide versus placebo in Chinese adults with type 2 diabetes. Nature. 2026. PMID: 41407859.
  6. 6.Hsia SH, Bays HE, Billings LK, Weideman AMK, Mather KJ, Coskun T, et al. Efficacy and safety of mazdutide in adults with obesity or overweight: a US-based, multicentre, phase 2, randomised, placebo-controlled clinical trial. Lancet Diabetes Endocrinol. 2026. PMID: 42628555.

GLP-1 Pipeline Tracker: Every Next-Gen Weight-Loss Drug in Development (2026)

A tracker of next-generation GLP-1 and incretin drugs: retatrutide, CagriSema, MariTide, survodutide, amycretin, mazdutide, ecnoglutide and the approved oral pill orforglipron (Foundayo), with stage and peak reported weight loss.

7 min read

Mazdutide (IBI362): GLP-1/Glucagon Dual Agonist Weight-Loss Evidence

Mazdutide is a GLP-1/glucagon dual agonist approved in China in 2025 for weight management (not FDA-approved). What the phase 3 GLORY-1 trial showed: -14% body weight at 48 weeks on 6 mg, how it compares to semaglutide and tirzepatide, and what its approval means for US patients.

9 min read

What Is Survodutide? The Glucagon/GLP-1 Dual Agonist in Phase 3

Survodutide is an investigational glucagon/GLP-1 dual agonist with phase 3 obesity data published in 2026. We cover the mechanism, the trial evidence in obesity and MASH, why no head-to-head against tirzepatide exists, and why there is no dose to follow.

5 min read

GLORY-2: How Much Weight Did Mazdutide 9 mg Produce?

In the phase 3 GLORY-2 trial, mazdutide 9 mg produced a mean weight change of −16.65% at 60 weeks versus −1.50% on placebo in Chinese adults with obesity. Here is why earlier reports said 18.55% or 20.1%, and how often vomiting and nausea occurred.

7 min read

Mounjaro Body Odor: The Evidence and the One Red Flag

Does Mounjaro cause body odor? Tirzepatide doesn't act on sweat glands — keto breath, dehydration, and dry mouth do. The honest mechanisms and the DKA red flag.

9 min read

What is GIP? GIP Receptor Explained (And Why Mounjaro/Zepbound Activate It Alongside GLP-1)

GIP (glucose-dependent insulinotropic polypeptide) is a gut hormone that drives, with GLP-1, the post-meal incretin effect. Tirzepatide (Mounjaro, Zepbound) is the first approved dual GIP/GLP-1 agonist and beat semaglutide in SURPASS-2.

13 min read

Where to get GLP-1 safely: vetted online providers

Vetted telehealth providers that prescribe online. We compare pricing, form, and states served.

No insurance needed · vetted by our editors

WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. How we make money

8.3

CoreAge Rx

Lowest-price compounded semaglutide and tirzepatide with one flat price at every dose

Read full review →

Pricing Compare

Get started →
7.8

Embody

Low flat-rate compounded GLP-1 pricing at every dose

Read full review →

Pricing Compare

Get started →
8.2

Gala

Compounded semaglutide or tirzepatide at one all-doses price on a yearly plan, with free shipping

Read full review →

Pricing Compare

Get started →